Kaufmann M, von Minckwitz G, Costa S
Klinik für Gynäkologie und Geburtshilfe, Universitäts-Frauenklinik, Frankfurt am Main.
Praxis (Bern 1994). 1998 Apr 8;87(15):529-30.
Breast cancer metastastic to sites beyond regional axillary lymph nodes represents a historically incurable condition despite the judicious use of various hormonal manipulations and surgical and radiotherapeutic interventions, and the application of active cytotoxic chemotherapeutic agents for hormone-refractory disease. The systemic management of patients with hormone refractory breast cancer is classically characterized by the thoughtful, stepwise administration of cytotoxic chemotherapeutic agents. At various junctures in the continuum of care, a patient/physician analysis of the potential risks and benefits of chemotherapy may lead to the decision to proceed with subsequent systemic therapy, to consider an investigational strategy like new active agents or high dose therapy, or to opt for supportive care alone.
乳腺癌转移至腋窝区域淋巴结以外的部位，在历史上一直是一种无法治愈的疾病，尽管已审慎采用了各种激素疗法、手术及放射治疗干预措施，并且针对激素难治性疾病应用了有效的细胞毒性化疗药物。激素难治性乳腺癌患者的全身治疗传统上的特点是谨慎、逐步地给予细胞毒性化疗药物。在连续治疗的各个阶段，患者/医生对化疗潜在风险和益处的分析可能会导致决定继续后续的全身治疗、考虑采用新的活性药物或高剂量治疗等研究性策略，或者仅选择支持性治疗。
